Aragen Bioscience, Inc. Sustainability Profile
Aragen Bioscience, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operational presence across various regions. Founded in 2001, the company has established itself as a trusted partner in the development of biologics, offering a comprehensive suite of services that includes cell line development, protein production, and analytical services. Aragen's unique approach combines cutting-edge technology with a commitment to quality, enabling clients to accelerate their drug development processes. The company has achieved notable milestones, including successful collaborations with major pharmaceutical firms, solidifying its position in the competitive biopharmaceutical landscape. With a focus on innovation and customer satisfaction, Aragen Bioscience continues to drive advancements in the industry, making it a preferred choice for organisations seeking reliable and efficient bioprocessing solutions.
DitchCarbon Score
How does Aragen Bioscience, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Bioscience, Inc.'s score of 89 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aragen Bioscience, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Aragen Life Sciences Limited, which may influence its climate commitments and emissions reporting. As of now, Aragen Bioscience has not established any documented reduction targets or specific climate pledges. The absence of emissions data and reduction initiatives suggests that the company is still in the early stages of formalising its climate strategy. Given its affiliation with Aragen Life Sciences Limited, any potential climate commitments or emissions data may be inherited from this parent organisation. However, specific details regarding emissions performance or reduction targets from Aragen Life Sciences Limited have not been disclosed. In the context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and are expected to adopt comprehensive climate strategies. As Aragen Bioscience continues to develop its environmental policies, stakeholders will be looking for future commitments to reduce carbon emissions and enhance sustainability practices.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Aragen Bioscience, Inc.'s Industry?
How Carbon Intensive is Aragen Bioscience, Inc.'s Location?
Aragen Bioscience, Inc.'s Scope 3 Categories Breakdown
Aragen Bioscience, Inc.'s Scope 3 emissions, which decreased by 26% last year and decreased by approximately 26% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 50% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Aragen Bioscience, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aragen Bioscience, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
